Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
Plos One
|
March 17, 2011
High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888
Susan K Lyman, Suzanne C Crawley, Ruoyu Gong, et al.
Journal of Medicinal Chemistry
|
November 23, 2017
Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques
Paola Di Lello, Richard Pastor, Jeremy M Murray, et al.
Cancer Research
|
March 30, 2013
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth
Ted Lau, Emily Chan, Marinella Callow, et al.
Cell Chemical Biology
|
May 20, 2026
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers
Wei Zhou, Musaddeque Ahmed, Jane Guan, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 18, 2019
Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927
Sharada S Labadie, Jun Li, Robert A Blake, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 9, 2019
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
Birong Zhang, James R Kiefer, Robert A Blake, et al.
Cell Chemical Biology
|
May 16, 2025
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
Anna Shemorry, Willem den Besten, Melinda M Mulvihill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Nature Communications
|
February 18, 2025
Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition
Sayantanee Paul, Thijs J Hagenbeek, Julien Tremblay, et al.
Nature Chemical Biology
|
December 28, 2022
Targeted degradation via direct 26S proteasome recruitment
Charlene Bashore, Sumit Prakash, Matthew C Johnson, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
Plos One
|
March 17, 2011
High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888
Susan K Lyman, Suzanne C Crawley, Ruoyu Gong, et al.
Journal of Medicinal Chemistry
|
November 23, 2017
Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques
Paola Di Lello, Richard Pastor, Jeremy M Murray, et al.
Cancer Research
|
March 30, 2013
A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth
Ted Lau, Emily Chan, Marinella Callow, et al.
Cell Chemical Biology
|
May 20, 2026
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers
Wei Zhou, Musaddeque Ahmed, Jane Guan, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 18, 2019
Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927
Sharada S Labadie, Jun Li, Robert A Blake, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 9, 2019
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha
Birong Zhang, James R Kiefer, Robert A Blake, et al.
Cell Chemical Biology
|
May 16, 2025
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
Anna Shemorry, Willem den Besten, Melinda M Mulvihill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Nature Communications
|
February 18, 2025
Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition
Sayantanee Paul, Thijs J Hagenbeek, Julien Tremblay, et al.
Nature Chemical Biology
|
December 28, 2022
Targeted degradation via direct 26S proteasome recruitment
Charlene Bashore, Sumit Prakash, Matthew C Johnson, et al.
Page
of 4